{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:45:14Z","timestamp":1792615514517,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82606011"],"award-info":[{"award-number":["82606011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20328"],"award-info":[{"award-number":["U22A20328"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573538"],"award-info":[{"award-number":["82573538"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019370","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["2024Y9418"],"award-info":[{"award-number":["2024Y9418"]}],"id":[{"id":"10.13039\/501100019370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019370","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["2024Y9420"],"award-info":[{"award-number":["2024Y9420"]}],"id":[{"id":"10.13039\/501100019370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.medj.2026.101331","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:05:14Z","timestamp":1792508714000},"page":"101331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic antitumor responses to hypofractionated radiotherapy plus Poly(I:C) in advanced hepatocellular carcinoma: A phase 2 trial"],"prefix":"10.1016","author":[{"given":"Liman","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6689-9264","authenticated-orcid":false,"given":"Qizhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinting","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1890-1141","authenticated-orcid":false,"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7883-2159","authenticated-orcid":false,"given":"Qiming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-4981","authenticated-orcid":false,"given":"Xiaolong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101331_bib1","first-page":"865","article-title":"[Analysis of global liver cancer statistics]","volume":"45","author":"Miao","year":"2024","journal-title":"Zhonghua Liuxingbingxue Zazhi"},{"key":"10.1016\/j.medj.2026.101331_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.medj.2026.101331_bib3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101331_bib4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101331_bib5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101331_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.14218\/JCTH.2018.00060","article-title":"Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma","volume":"7","author":"Chen","year":"2019","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.medj.2026.101331_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705361","article-title":"Immunogenic Cell Death Induction by Ionizing Radiation","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2026.101331_bib8","article-title":"Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum","volume":"5","author":"Ingels","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.medj.2026.101331_bib9","article-title":"Radiotherapy-induced alterations in tumor microenvironment: metabolism and immunity","volume":"13","author":"Chen","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.medj.2026.101331_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.currproblcancer.2015.10.001","article-title":"Systematic review of case reports on the abscopal effect","volume":"40","author":"Abuodeh","year":"2016","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.medj.2026.101331_bib11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.medj.2026.101331_bib12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/cancers18030408","article-title":"Unexpected Therapeutic Implications: The Abscopal Effect in the Management of Hepatocellular Carcinoma","volume":"18","author":"Cerrito","year":"2026","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.medj.2026.101331_bib13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.medj.2026.101331_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011061","article-title":"The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances","volume":"22","author":"Janopaul-Naylor","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.medj.2026.101331_bib15","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.3390\/cancers14215190","article-title":"A Systematic Review on the Impact of Hypofractionated and Stereotactic Radiotherapy on Immune Cell Subpopulations in Cancer Patients","volume":"14","author":"Takanen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.medj.2026.101331_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40364-024-00628-3","article-title":"Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy","volume":"12","author":"Wang","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.medj.2026.101331_bib17","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s12072-022-10396-7","article-title":"Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial","volume":"16","author":"Li","year":"2022","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.medj.2026.101331_bib18","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41467-025-67528-4","article-title":"Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial","volume":"17","author":"Tang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101331_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2026.101331_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.medj.2026.101331_bib21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12026-021-09203-6","article-title":"TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review","volume":"69","author":"Komal","year":"2021","journal-title":"Immunol. Res."},{"key":"10.1016\/j.medj.2026.101331_bib22","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1038\/s41467-022-34602-0","article-title":"TLR3 forms a highly organized cluster when bound to a poly(I:C) RNA ligand","volume":"13","author":"Lim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101331_bib23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-021-01467-8","article-title":"Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion","volume":"20","author":"Cai","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.medj.2026.101331_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/JCI151239","article-title":"Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas","volume":"132","author":"Ogino","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101331_bib25","article-title":"Trial watch: TLR3 agonists in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.medj.2026.101331_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/JHC.S136652","article-title":"A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect","volume":"4","author":"de la Torre","year":"2017","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.medj.2026.101331_bib27","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/s44321-024-00068-4","article-title":"TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis","volume":"16","author":"Qiu","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.medj.2026.101331_bib28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity Analysis in Observational Research: Introducing the E-Value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.medj.2026.101331_bib29","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.3390\/ijms22115801","article-title":"Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review","volume":"22","author":"Oura","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.medj.2026.101331_bib30","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/25785826.2021.1997268","article-title":"Radiotherapy driven immunomodulation of the tumor microenvironment and its impact on clinical outcomes: a promising new treatment paradigm","volume":"45","author":"Mahmood","year":"2022","journal-title":"Immunol. Med."},{"key":"10.1016\/j.medj.2026.101331_bib31","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.1038\/s41467-022-34477-1","article-title":"Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101331_bib32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.0105-2896.2005.00256.x","article-title":"CD28 extinction in human T cells: altered functions and the program of T-cell senescence","volume":"205","author":"Vallejo","year":"2005","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.medj.2026.101331_bib33","article-title":"New emerging targets in cancer immunotherapy: CD137\/4-1BB costimulatory axis","volume":"4","author":"Etxeberria","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.medj.2026.101331_bib34","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41416-021-01330-z","article-title":"Vascular normalisation as the stepping stone into tumour microenvironment transformation","volume":"125","author":"Magnussen","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2026.101331_bib35","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.3390\/curroncol30050360","article-title":"Vascular Normalization Caused by Short-Term Lenvatinib Could Enhance Transarterial Chemoembolization in Hepatocellular Carcinoma","volume":"30","author":"Tachiiri","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.medj.2026.101331_bib36","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","article-title":"Targeting the tumour vasculature: from vessel destruction to promotion","volume":"24","author":"Guelfi","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.medj.2026.101331_bib37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.medj.2026.101331_bib38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41416-020-0942-3","article-title":"Radiation-induced bystander and abscopal effects: important lessons from preclinical models","volume":"123","author":"Daguenet","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2026.101331_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1125876","article-title":"Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1\/PD-L1 inhibitors in cancer patients","volume":"14","author":"Geng","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2026.101331_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg0878","article-title":"Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1(+) PD-1(+) CD8 T cells","volume":"8","author":"Humblin","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.medj.2026.101331_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/JHC.S432948","article-title":"First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison","volume":"11","author":"Mahn","year":"2024","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.medj.2026.101331_bib42","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101331_bib43","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/cancers15061680","article-title":"Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives","volume":"15","author":"Girardi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.medj.2026.101331_bib44","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000499765","article-title":"Systemic Treatment Options in Hepatocellular Carcinoma","volume":"8","author":"Rimassa","year":"2019","journal-title":"Liver Cancer"},{"key":"10.1016\/j.medj.2026.101331_bib45","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.gpb.2021.08.001","article-title":"The Genome Sequence Archive Family: Toward Explosive Data Growth and Diverse Data Types","volume":"19","author":"Chen","year":"2021","journal-title":"Genom. Proteom. Bioinform."},{"key":"10.1016\/j.medj.2026.101331_bib46","doi-asserted-by":"crossref","first-page":"D18","DOI":"10.1093\/nar\/gkad1078","article-title":"Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2024","volume":"52","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.medj.2026.101331_bib48","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","article-title":"CellChat for systematic analysis of cell\u2013cell communication from single-cell transcriptomics","volume":"20","author":"Jin","year":"2025","journal-title":"Nat Protoc"},{"key":"10.1016\/j.medj.2026.101331_bib47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","article-title":"Balancing Covariates via Propensity Score Weighting","volume":"113","author":"Li","year":"2018","journal-title":"J. Am. Stat. Assoc."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663402600334X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663402600334X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:01:46Z","timestamp":1792612906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663402600334X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"alternative-id":["S266663402600334X"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101331","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic antitumor responses to hypofractionated radiotherapy plus Poly(I:C) in advanced hepatocellular carcinoma: A phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101331"}}